Skip to main content
. 2016 Nov 14;6:36956. doi: 10.1038/srep36956

Figure 3.

Figure 3

(A) The 5-year recurrence-free survival (RFS) rate was 72.4% for PD-L1-positive tumor cells (TC) vs. 65.6% for PD-L1-negative TC; P = 0.206. (B) The 5-year overall survival (OS) rate was 80.1% for PD-L1-positive TC vs. 77.7% for PD-L1-negative TC; P = 0.317. (C) The 5-year RFS rate was 69.7% for PD-L1-negative immune cells (IC) vs. 80.1% for PD-L1-positive IC; P = 0.005. (D) The 5-year OS rate was 75.6% for PD-L1-negative IC vs. 90.6% for PD-L1-positive IC; P = 0.003. (E) PD-L1 expression on TC and IC was categorized into four groups according to the percentage of positive cells: TC0 or IC0, 0%; TC1 or IC1, >0% but <5%; TC2 or IC2, ≥5% but <50%; and TC3 or IC3, ≥50%. The counts (frequencies) of TC1/2/3 and IC1/2/3 were 129/402 (32.1%) and 201/402 (50%), respectively, and the overlap between TC1/2/3 and IC1/2/3 was 103/402 (25.6%). The counts (frequencies) of TC2/3 and IC2/3 were 73/402 (18.2%) and 112/402 (27.9%), and the overlap between these two groups was 40/402 (10%). Notably, the counts (frequencies) of TC3 and IC3 were 10/402 (2.5%) and 28/402 (7.0%), respectively, and the overlap between TC3 and IC3 was only 1/402 (0.2%).